Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Bankrupt genetic testing company 23andMe has been sold to Regeneron Pharmaceuticals for $256 million. The deal includes ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection. In March 23andMe said ...

SAN FRANCISCO, (GLOBE NEWSWIRE) --  23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered into a ...